Clinical trials
Multiple Myeloma trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
152 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 11 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 13 |
| 2022 | 15 |
| 2023 | 14 |
| 2024 | 9 |
| 2025 | 4 |
| 2026 | 11 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
| Active, not recruiting | 33 |
| Recruiting | 31 |
| Terminated | 17 |
| No longer available | 1 |
| Withdrawn | 1 |
| Approved for marketing | 1 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 21 |
| Celgene | 19 |
| AbbVie | 17 |
| Bristol-Myers Squibb | 11 |
| Pfizer | 11 |
| Amgen | 9 |
| GlaxoSmithKline | 9 |
| Novartis Pharmaceuticals | 9 |
| Sanofi | 9 |
| Janssen Pharmaceutical K.K. | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 152 |
| Recurrence | 30 |
| Neoplasms | 15 |
| Leukemia, Myeloid, Acute | 8 |
| Lymphoma, Non-Hodgkin | 8 |
| Lymphoma | 5 |
| Neoplasms, Plasma Cell | 5 |
| Myelodysplastic Syndromes | 4 |
| Arrhythmias, Cardiac | 3 |
| Heart Failure | 3 |
Trials
Showing 51 to 75 of 152. Each trial links to its page on Pharma Observatory.
52 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.